...
首页> 外文期刊>Cytokine >Attenuated in vitro effects of IFN-alpha, IL-2 and IL-12 on functional and receptor characteristics of peripheral blood lymphocytes in metastatic melanoma patients
【24h】

Attenuated in vitro effects of IFN-alpha, IL-2 and IL-12 on functional and receptor characteristics of peripheral blood lymphocytes in metastatic melanoma patients

机译:IFN-α,IL-2和IL-12对转移性黑素瘤患者外周血淋巴细胞功能和受体特性的体外效果

获取原文
获取原文并翻译 | 示例

摘要

Considering tumor-induced suppression of lymphocytes the aim of this study was to investigate in vitro effects of IFN-alpha, IL-2, IL-12 and IL-18 as immunomodulating agents on the functional and receptor characteristics of peripheral blood lymphocytes (PBL) in metastatic melanoma (MM) patients compared to healthy controls (HC). In HC IFN-alpha, IL-2 and IL-12 enhanced mRNA level of perforin by inducing pSTAT-1 and pSTAT-5 signaling molecules. Additionally, the expression of NKG2D activating receptor and its DAP10 signaling molecule was upregulated by IL-2. Contrary to this, in MM patients only IL-2 by upregulating pSTAT-5 increased perforin-mediated cytotoxicity of lymphocytes. Furthermore, there was significantly negative correlation between the percentage of CD4(+)CD25(bright+)CD27(+) regulatory T (Treg) cells and NK cell cytotoxicity, as well as the expression of NKG2D receptor on PBL in HC and MM patients. Therefore, the absence of IL-2 effect on the increase of NKG2D/DAP10 level in MM patients could be the consequence of the increased percentage of immunosuppressive CD4(+)CD25(bright+)CD27(+) cells after this cytokine treatment in patients. However, in MM IL-12 significantly decreases the percentage of these inhibitory cells. Although IL-2 as a single agent has numerous side effects, it remains the important cytokine for PBL activation in melanoma immunotherapy. Additionally, the removal of Treg cells from patient PBL by IL-12 before in vitro stimulation with IL-2, may lead to the generation of more potent cytotoxic lymphocytes against tumor cells. Therefore, lymphocyte based therapy for MM patients should integrate not only the choice of appropriate immunostimulatory cytokine, but also the removal of inhibitory cells from tumor microenvironment. (C) 2017 Elsevier Ltd. All rights reserved.
机译:考虑肿瘤诱导的淋巴细胞抑制该研究的目的是研究IFN-α,IL-2,IL-12和IL-18在外周血淋巴细胞的功能和受体特征上的免疫调节剂的体外影响(PBL)在转移性黑色素瘤(mm)患者中,与健康对照(HC)相比。在HC IFN-α-α,IL-2和IL-12通过诱导PSTAT-1和PSTAT-5信号分子增强穿孔素的mRNA水平。另外,通过IL-2上调NKG2D活化受体及其DAP10信号传导分子的表达。与此相反,通过上调PSTAT-5增加了IL-2,增加了淋巴细胞的淋巴细胞细胞毒性。此外,CD4(+)CD25(亮+)CD27(+)细胞和NK细胞毒性的百分比与NKG2D受体在HC和MM患者中的NKG2D受体表达之间存在显着的负相关性。因此,在MM患者中没有IL-2对NKG2D / DAP10水平的影响可能是免疫抑制CD4(+)CD25(+)CD27(+)细胞在患者中这种细胞因子治疗后增加的结果。然而,在MM IL-12中显着降低了这些抑制细胞的百分比。虽然IL-2作为单一剂具有许多副作用,但它仍然是黑素瘤免疫疗法中PBL活化的重要细胞因子。另外,在用IL-2体外刺激之前通过IL-12从患者PBL中除去Treg细胞,可能导致对肿瘤细胞产生更有效的细胞毒性淋巴细胞。因此,MM患者的淋巴细胞治疗不仅应融合适当的免疫刺激性细胞因子,还应结合来自肿瘤微环境的抑制细胞。 (c)2017 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号